Healthcare provider profile · identity verified

Edwin Werner Zevallos, M.D.

Internal Medicine · HUNTINGTON PARK, CA · NPI 1518042498

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	813	212
Losartan Potassium	Losartan Potassium	465	118
Metformin Hcl	Metformin Hcl	451	114
Amlodipine Besylate	Amlodipine Besylate	416	113
Omeprazole	Omeprazole	320	91
Alendronate Sodium	Alendronate Sodium	236	58
Hydrochlorothiazide	Hydrochlorothiazide	192	49
Pantoprazole Sodium	Pantoprazole Sodium	191	49
Azithromycin	Azithromycin	185	121
Furosemide	Furosemide	180	47
Benazepril Hcl	Benazepril Hcl	177	45
Lisinopril	Lisinopril	174	49
Glipizide	Glipizide	171	44
Levothyroxine Sodium	Levothyroxine Sodium	169	44
Januvia	Sitagliptin Phosphate	147	29
Alcohol Prep Pads	Alcohol Antiseptic Pads	138	54
Jardiance	Empagliflozin	133	24
Meloxicam	Meloxicam	132	62
Simvastatin	Simvastatin	127	34
Citalopram Hbr	Citalopram Hydrobromide	120	27
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	118	88
Metoprolol Succinate	Metoprolol Succinate	109	34
Metoprolol Tartrate	Metoprolol Tartrate	109	30
Icosapent Ethyl	Icosapent Ethyl	105	36
Farxiga	Dapagliflozin Propanediol	96	24
Tamsulosin Hcl	Tamsulosin Hcl	91	25
Diclofenac Sodium	Diclofenac Sodium	83	41
Rosuvastatin Calcium	Rosuvastatin Calcium	81	26
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	80	56
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	76	26
Gabapentin	Gabapentin	72	27
Pioglitazone Hcl	Pioglitazone Hcl	70	17
Albuterol Sulfate Hfa	Albuterol Sulfate	66	25
Vascepa	Icosapent Ethyl	66	20
Clopidogrel	Clopidogrel Bisulfate	63	14
Ezetimibe	Ezetimibe	58	16
Carvedilol	Carvedilol	57	17
Tradjenta	Linagliptin	56	suppressed
Atenolol	Atenolol	54	15
Eliquis	Apixaban	54	11
Meclizine Hcl	Meclizine Hcl	54	31
Famotidine	Famotidine	51	12
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	50	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	50	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	45	13
Enalapril Maleate	Enalapril Maleate	41	suppressed
Hydrocortisone	Hydrocortisone	41	19
Cephalexin	Cephalexin	40	27
Irbesartan	Irbesartan	35	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	34	26
Comfort Ez Pen Needle	Pen Needle, Diabetic	34	12
Montelukast Sodium	Montelukast Sodium	34	suppressed
Finasteride	Finasteride	33	11
Fenofibrate	Fenofibrate	32	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	30	21
Hydralazine Hcl	Hydralazine Hcl	30	suppressed
Potassium Chloride	Potassium Chloride	29	suppressed
Naproxen	Naproxen	27	11
Triamcinolone Acetonide	Triamcinolone Acetonide	26	11
Chlorthalidone	Chlorthalidone	23	suppressed
Dutasteride	Dutasteride	23	suppressed
Celecoxib	Celecoxib	22	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	22	suppressed
Symbicort	Budesonide/Formoterol Fumarate	20	suppressed
Warfarin Sodium	Warfarin Sodium	20	suppressed
Glimepiride	Glimepiride	19	suppressed
Ventolin Hfa	Albuterol Sulfate	19	suppressed
Clotrimazole	Clotrimazole	17	14
Dexlansoprazole Dr	Dexlansoprazole	17	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Lansoprazole	Lansoprazole	17	suppressed
Linzess	Linaclotide	17	suppressed
Allopurinol	Allopurinol	16	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	16	11
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	16	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	15	suppressed
Labetalol Hcl	Labetalol Hcl	15	suppressed
Rybelsus	Semaglutide	15	suppressed
Ibuprofen	Ibuprofen	14	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	14	suppressed
Invokana	Canagliflozin	13	suppressed
Terbinafine Hcl	Terbinafine Hcl	13	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	12	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	12	suppressed
Levofloxacin	Levofloxacin	11	suppressed
Sucralfate	Sucralfate	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error